Automate Your Wheel Strategy on BSX
With Tiblio's Option Bot, you can configure your own wheel strategy including BSX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BSX
- Rev/Share 11.8826
- Book/Share 15.195
- PB 6.9018
- Debt/Equity 0.5271
- CurrentRatio 1.4502
- ROIC 0.0701
- MktCap 153537321000.0
- FreeCF/Share 1.9449
- PFCF 53.4415
- PE 75.4448
- Debt/Assets 0.2917
- DivYield 0
- ROE 0.0956
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BSX | Leerink Partners | -- | Outperform | -- | $118 | June 16, 2025 |
| Upgrade | BSX | Needham | Hold | Buy | -- | $113 | April 16, 2025 |
| Upgrade | BSX | Deutsche Bank | Hold | Buy | -- | $108 | Jan. 10, 2025 |
| Downgrade | BSX | Needham | Buy | Hold | -- | -- | Oct. 18, 2024 |
News
Exploring Analyst Estimates for Boston Scientific (BSX) Q2 Earnings, Beyond Revenue and EPS
Published: July 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Besides Wall Street's top-and-bottom-line estimates for Boston Scientific (BSX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2025.
Read More
PAHC or BSX: Which Is the Better Value Stock Right Now?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
Boston Scientific (BSX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific (BSX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Will Robust MedSurg Performance Fuel Boston Scientific's Q2 Earnings?
Published: July 15, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX eyes strong Q2 with MedSurg momentum, solid Cardiovascular growth and benefits from key tech acquisitions.
Read More
3 AI-Driven Medical Device Stocks to Watch in 2025
Published: July 11, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX, JNJ and GEHC are leveraging AI to boost device performance, diagnostics and surgical precision in 2025.
Read More
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
Is it Worth Adding Boston Scientific Stock to Your Portfolio Now?
Published: July 10, 2025 by: Zacks Investment Research
Sentiment: Negative
BSX rides on strong MedSurg growth and strategic acquisitions amid currency headwinds.
Read More
Will Boston Scientific (BSX) Beat Estimates Again in Its Next Earnings Report?
Published: July 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific (BSX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Boston Scientific Climbs 40.5% in a Year: What's Driving the Stock?
Published: July 01, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX rallies 40.5% in a year, fueled by WATCHMAN growth, MedSurg gains, acquisitions and global expansion efforts.
Read More
PAHC vs. BSX: Which Stock Is the Better Value Option?
Published: June 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks offers value investors a better bang for their buck right now?
Read More
BSX vs. MDT: Which MedSurg Stock Is the Better Investment Now?
Published: June 26, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two prominent companies with a strong foothold in this space are Boston Scientific BSX and Medtronic MDT.
Read More
Brokers Suggest Investing in Boston Scientific (BSX): Read This Before Placing a Bet
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Read More
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Read More
BSX Raises 2025 Financial Outlook: What's Backing It?
Published: June 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific lifts its 2025 sales and EPS outlook after a strong Q1, with cardiology and EP segments fueling major gains.
Read More
BSX's Neuromodulation Arm Sees Growth: Q1 Highlights
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific's Neuromodulation unit witnesses 6.8% growth in the first quarter, fueled by strong gains in pain and brain therapy lines.
Read More
ISRG vs BSX: Which Medical Device Stock Has More Room to Run?
Published: June 18, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific offers steady growth with broader exposure, while Intuitive Surgical leads in robotics but faces margin and tariff headwinds.
Read More
What's Happening With Boston Scientific Stock?
Published: June 16, 2025 by: Forbes
Sentiment: Positive
Boston Scientific (NYSE:BSX) has experienced a stock price increase of over 30% in the last twelve months, greatly exceeding the S&P 500's gain of 9%. This remarkable performance can be credited to the launch of new products, which have enhanced sales growth and widened profit margins.
Read More
PAHC vs. BSX: Which Stock Should Value Investors Buy Now?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks is more attractive to value investors?
Read More
BSX Q1 Endoscopy Sales Rise 6%: What's Behind the Growth?
Published: June 13, 2025 by: Zacks Investment Research
Sentiment: Neutral
Boston Scientific's Q1 2025 Endoscopy sales jump 6%, powered by innovation in stents, clips and surgical tools for GI care.
Read More
Cardiovascular Tailwind Boosts BSX: Here's How to Play the Stock
Published: June 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific BSX, a prominent global player in cardiovascular technology, is well-positioned to capitalize on the robust expansion of the cardiovascular devices market. According to a MarketsandMarkets report, this market was valued at $72.83 billion in 2023 and is expected to witness a strong CAGR of 7.3% between 2024 and 2029.
Read More
Boston Scientific (BSX) Upgraded to Buy: Here's Why
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific (BSX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Here is how Boston Scientific (BSX) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.
Read More
Wall Street Bulls Look Optimistic About Boston Scientific (BSX): Should You Buy?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Neutral
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Read More
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the most recent trading session, Boston Scientific (BSX) closed at $102.43, indicating a -0.65% shift from the previous trading day.
Read More
Profit From the Silver Tsunami: Must-Watch Senior Care & Aging Stocks
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX, ABBV, AMGN and DXCM are tapping into the aging boom with cutting-edge tech, chronic care drugs and senior-focused innovations.
Read More
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Emerging Markets Power Boston Scientific: Will the Growth Trend Continue?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX posts solid Q1 sales growth in emerging markets, reinforcing their role in the company's long-term global strategy.
Read More
Boston Scientific (BSX) Stock Declines While Market Improves: Some Information for Investors
Published: May 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
In the latest trading session, Boston Scientific (BSX) closed at $104.50, marking a -0.01% move from the previous day.
Read More
Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook
Published: May 28, 2025 by: Benzinga
Sentiment: Negative
Boston Scientific Corporation BSX is pulling the plug on its ACURATE neo2 and Prime aortic valve systems.
Read More
About Boston Scientific Corporation (BSX)
- IPO Date 1992-05-19
- Website https://www.bostonscientific.com
- Industry Medical - Devices
- CEO Michael F. Mahoney
- Employees 53000